Department of Medicine, Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
BMC Nephrol. 2012 Jun 15;13:42. doi: 10.1186/1471-2369-13-42.
The Chronic Kidney Disease Epidemiology Collaboration equation for estimation of glomerular filtration rate (eGFR(CKD-EPI)) improves GFR estimation compared with the Modification of Diet in Renal Disease Study equation (eGFR(MDRD)) but its association with mortality in a nationally representative population sample in the US has not been studied.
We examined the association between eGFR and mortality among 16,010 participants of the Third National Health and Nutrition Examination Survey (NHANES III). Primary predictors were eGFR(CKD-EPI) and eGFR(MDRD). Outcomes of interest were all-cause and cardiovascular disease (CVD) mortality. Improvement in risk categorization with eGFR(CKD-EPI) was evaluated using adjusted relative hazard (HR) and Net Reclassification Improvement (NRI).
Overall, 26.9% of the population was reclassified to higher eGFR categories and 2.2% to lower eGFR categories by eGFR(CKD-EPI), reducing the proportion of prevalent CKD classified as stage 3-5 from 45.6% to 28.8%. There were 3,620 deaths (1,540 from CVD) during 215,082 person-years of follow-up (median, 14.3 years). Among those with eGFR(MDRD) 30-59 ml/min/1.73 m(2), 19.4% were reclassified to eGFR(CKD-EPI) 60-89 ml/min/1.73 m(2) and these individuals had a lower risk of all-cause mortality (adjusted HR, 0.53; 95% CI, 0.34-0.84) and CVD mortality (adjusted HR, 0.51; 95% CI, 0.27-0.96) compared with those not reclassified. Among those with eGFR(MDRD) >60 ml/min/1.73 m(2), 0.5% were reclassified to lower eGFR(CKD-EPI) and these individuals had a higher risk of all-cause (adjusted HR, 1.31; 95% CI, 1.01-1.69) and CVD (adjusted HR, 1.42; 95% CI, 1.01-1.99) mortality compared with those not reclassified. Risk prediction improved with eGFR(CKD-EPI); NRI was 0.21 for all-cause mortality (p < 0.001) and 0.22 for CVD mortality (p < 0.001).
eGFR(CKD-EPI) categories improve mortality risk stratification of individuals in the US population. If eGFR(CKD-EPI) replaces eGFR(MDRD) in the US, it will likely improve risk stratification.
与改良肾脏病饮食研究方程(eGFR(MDRD))相比,慢性肾脏病流行病学合作方程(eGFR(CKD-EPI))可更准确地估算肾小球滤过率(GFR)。但在对美国具有代表性的全国性人群样本中,eGFR(CKD-EPI)与死亡率的相关性尚未得到研究。
我们对第三次全国健康和营养检查调查(NHANES III)中的 16010 名参与者的 eGFR 与死亡率之间的关系进行了研究。主要预测因素是 eGFR(CKD-EPI)和 eGFR(MDRD)。研究的结局是全因死亡率和心血管疾病(CVD)死亡率。通过调整后的相对危险(HR)和净重新分类改善(NRI)评估了 eGFR(CKD-EPI)在风险分类中的改善。
总体而言,eGFR(CKD-EPI)将 26.9%的人群重新分类为更高的 eGFR 类别,2.2%的人群重新分类为更低的 eGFR 类别,从而将 eGFR(MDRD)分类为 3-5 期的 CKD 比例从 45.6%降低至 28.8%。在 215082 人年的随访期间(中位数为 14.3 年),共发生 3620 例死亡(1540 例死于 CVD)。在 eGFR(MDRD)为 30-59 ml/min/1.73 m2的人群中,有 19.4%被重新分类为 eGFR(CKD-EPI)为 60-89 ml/min/1.73 m2,这些人全因死亡率(调整后的 HR,0.53;95%CI,0.34-0.84)和 CVD 死亡率(调整后的 HR,0.51;95%CI,0.27-0.96)的风险降低。在 eGFR(MDRD)>60 ml/min/1.73 m2的人群中,有 0.5%的人被重新分类为较低的 eGFR(CKD-EPI),这些人全因死亡率(调整后的 HR,1.31;95%CI,1.01-1.69)和 CVD 死亡率(调整后的 HR,1.42;95%CI,1.01-1.99)的风险升高。与未重新分类的人群相比。eGFR(CKD-EPI)改善了风险预测;全因死亡率的 NRI 为 0.21(p < 0.001),CVD 死亡率的 NRI 为 0.22(p < 0.001)。
eGFR(CKD-EPI)类别可改善美国人群中个体的死亡率风险分层。如果 eGFR(CKD-EPI)在美国取代 eGFR(MDRD),则可能改善风险分层。